CpG Island Methylation, Response to Combination Chemotherapy, and Patient Survival in Advanced Microsatellite Stable Colorectal Carcinoma

Overview

Journal Virchows Arch

Specialties Cell Biology
Molecular Biology
Pathology

Date 2007 Mar 21

PMID 17372756

Citations 61

Authors

Shuji Ogino

Jeffrey A Meyerhardt

Takako Kawasaki

Jeffrey W Clark

David P Ryan

Matthew H Kulke

Peter C Enzinger

Brian M Wolpin

Massimo Loda

Charles S Fuchs

Affiliations

Soon will be listed here.

Abstract

The CpG island methylator phenotype (CIMP) is a distinct epigenetic phenotype in colorectal carcinoma with concordant methylation in multiple promoter CpG islands. The relationship between CpG island methylation and clinical outcomes among colorectal cancer patients treated with chemotherapy has been a controversial subject. Utilizing real-time polymerase chain reaction (PCR; MethyLight technology), we quantified DNA methylation in 13 CpG island loci (CACNA1G, CDKN2A, CRABP1, IGF2, MLH1, NEUROG1, RUNX3, SOCS1, MINT1, MINT31, IGFBP3, MGMT, and WRN) in 30 metastatic microsatellite stable colorectal carcinomas in phase I/II clinical trials of combination chemotherapy (5-fluorouracil, irinotecan, leucovorin, and gefitinib). Tumor response was assessed by CT scans performed at baseline and every 6 weeks thereafter. Overall CIMP-high status (either >or=9/13 or >or=7/13 methylated markers; identifying 3 or 5 CIMP-high tumors, respectively) and methylation in CACNA1G, IGF2, MLH1, NEUROG1, RUNX3, MINT31, and WRN were associated with worse survival (all p < 0.01). Although not statistically significant, there was a trend toward resistance to chemotherapy among tumors with CpG island methylation. In conclusion, CpG island methylation may predict poor survival in metastatic microsatellite stable colorectal carcinoma treated with chemotherapy. Additional studies are necessary to examine the role of DNA methylation in treatment efficacy.

Citing Articles

Genome-wide DNA methylation status is a predictor of the efficacy of anti-EGFR antibodies in the second-line treatment of metastatic colorectal cancer: Translational research of the EPIC trial.

Ouchi K, Takahashi S, Sasaki K, Yoshida Y, Taniguchi S, Kasahara Y Int J Colorectal Dis. 2024; 39(1):89.

PMID: 38862615 PMC: 11166830. DOI: 10.1007/s00384-024-04659-y.

High Expression of IRS-1, RUNX3 and SMAD4 Are Positive Prognostic Factors in Stage I-III Colon Cancer.

Selven H, Rasmussen Busund L, Andersen S, Pedersen M, Lombardi A, Kilvaer T Cancers (Basel). 2023; 15(5).

PMID: 36900240 PMC: 10000923. DOI: 10.3390/cancers15051448.

The paradoxical roles of miR-4295 in human cancer: Implications in pathogenesis and personalized medicine.

Li Y, Zhang Y, Zou Y, Duan S Genes Dis. 2022; 9(3):638-647.

PMID: 35782974 PMC: 9243315. DOI: 10.1016/j.gendis.2020.09.007.

Transcription factors in colorectal cancer: molecular mechanism and therapeutic implications.

Xu H, Liu L, Li W, Zou D, Yu J, Wang L Oncogene. 2020; 40(9):1555-1569.

PMID: 33323976 DOI: 10.1038/s41388-020-01587-3.

Epigenetic Alterations in the Gastrointestinal Tract: Current and Emerging Use for Biomarkers of Cancer.

Grady W, Yu M, Markowitz S Gastroenterology. 2020; 160(3):690-709.

PMID: 33279516 PMC: 7878343. DOI: 10.1053/j.gastro.2020.09.058.

References

Ogino S, Brahmandam M, Cantor M, Namgyal C, Kawasaki T, Kirkner G . Distinct molecular features of colorectal carcinoma with signet ring cell component and colorectal carcinoma with mucinous component. Mod Pathol. 2005; 19(1):59-68. DOI: 10.1038/modpathol.3800482. View

Ogino S, Cantor M, Kawasaki T, Brahmandam M, Kirkner G, Weisenberger D . CpG island methylator phenotype (CIMP) of colorectal cancer is best characterised by quantitative DNA methylation analysis and prospective cohort studies. Gut. 2006; 55(7):1000-6. PMC: 1856352. DOI: 10.1136/gut.2005.082933. View

Widschwendter M, Siegmund K, Muller H, Fiegl H, Marth C, Muller-Holzner E . Association of breast cancer DNA methylation profiles with hormone receptor status and response to tamoxifen. Cancer Res. 2004; 64(11):3807-13. DOI: 10.1158/0008-5472.CAN-03-3852. View

Therasse P, Arbuck S, Eisenhauer E, Wanders J, Kaplan R, Rubinstein L . New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92(3):205-16. DOI: 10.1093/jnci/92.3.205. View

Ogino S, Kawasaki T, Brahmandam M, Cantor M, Kirkner G, Spiegelman D . Precision and performance characteristics of bisulfite conversion and real-time PCR (MethyLight) for quantitative DNA methylation analysis. J Mol Diagn. 2006; 8(2):209-17. PMC: 1867588. DOI: 10.2353/jmoldx.2006.050135. View

Wiley A, Katsaros D, Fracchioli S, Yu H . Methylation of the insulin-like growth factor binding protein-3 gene and prognosis of epithelial ovarian cancer. Int J Gynecol Cancer. 2006; 16(1):210-8. DOI: 10.1111/j.1525-1438.2006.00299.x. View

Toyota M, Ahuja N, Herman J, Baylin S, Issa J . CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci U S A. 1999; 96(15):8681-6. PMC: 17576. DOI: 10.1073/pnas.96.15.8681. View

Ogino S, Kawasaki T, Brahmandam M, Yan L, Cantor M, Namgyal C . Sensitive sequencing method for KRAS mutation detection by Pyrosequencing. J Mol Diagn. 2005; 7(3):413-21. PMC: 1867544. DOI: 10.1016/S1525-1578(10)60571-5. View

Toyooka K, Toyooka S, Maitra A, Feng Q, Kiviat N, Smith A . Establishment and validation of real-time polymerase chain reaction method for CDH1 promoter methylation. Am J Pathol. 2002; 161(2):629-34. PMC: 1850730. DOI: 10.1016/S0002-9440(10)64218-6. View

10.

Chang Y, Wang L, Liu D, Mao L, Hong W, Khuri F . Correlation between insulin-like growth factor-binding protein-3 promoter methylation and prognosis of patients with stage I non-small cell lung cancer. Clin Cancer Res. 2002; 8(12):3669-75. View

11.

Arnold C, Goel A, Boland C . Role of hMLH1 promoter hypermethylation in drug resistance to 5-fluorouracil in colorectal cancer cell lines. Int J Cancer. 2003; 106(1):66-73. DOI: 10.1002/ijc.11176. View

12.

Laird P . Cancer epigenetics. Hum Mol Genet. 2005; 14 Spec No 1:R65-76. DOI: 10.1093/hmg/ddi113. View

13.

Samowitz W, Albertsen H, Herrick J, Levin T, Sweeney C, Murtaugh M . Evaluation of a large, population-based sample supports a CpG island methylator phenotype in colon cancer. Gastroenterology. 2005; 129(3):837-45. DOI: 10.1053/j.gastro.2005.06.020. View

14.

Bacher J, Flanagan L, Smalley R, Nassif N, Burgart L, Halberg R . Development of a fluorescent multiplex assay for detection of MSI-High tumors. Dis Markers. 2004; 20(4-5):237-50. PMC: 3839403. DOI: 10.1155/2004/136734. View

15.

Samowitz W, Sweeney C, Herrick J, Albertsen H, Levin T, Murtaugh M . Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. Cancer Res. 2005; 65(14):6063-9. DOI: 10.1158/0008-5472.CAN-05-0404. View

16.

Issa J . CpG island methylator phenotype in cancer. Nat Rev Cancer. 2004; 4(12):988-93. DOI: 10.1038/nrc1507. View

17.

Ward R, Cheong K, Ku S, Meagher A, OConnor T, Hawkins N . Adverse prognostic effect of methylation in colorectal cancer is reversed by microsatellite instability. J Clin Oncol. 2003; 21(20):3729-36. DOI: 10.1200/JCO.2003.03.123. View

18.

Dietmaier W, Hartmann A, Wallinger S, Heinmoller E, Kerner T, Endl E . Multiple mutation analyses in single tumor cells with improved whole genome amplification. Am J Pathol. 1999; 154(1):83-95. PMC: 1853424. DOI: 10.1016/S0002-9440(10)65254-6. View

19.

Agrelo R, Cheng W, Setien F, Ropero S, Espada J, Fraga M . Epigenetic inactivation of the premature aging Werner syndrome gene in human cancer. Proc Natl Acad Sci U S A. 2006; 103(23):8822-7. PMC: 1466544. DOI: 10.1073/pnas.0600645103. View

20.

Toyota M, Ahuja N, Issa J . Distinct genetic profiles in colorectal tumors with or without the CpG island methylator phenotype. Proc Natl Acad Sci U S A. 2000; 97(2):710-5. PMC: 15395. DOI: 10.1073/pnas.97.2.710. View